搜索优化
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
过去 30 天
时间不限
过去 1 小时
过去 24 小时
过去 7 天
按时间排序
按相关度排序
9 小时
on MSN
Outcry over Labour's plans for free weight loss jabs on the NHS
Health secretary Wes Streeting has backed the prescribing of the drugs to obese patients in the hope it can tackle the nation ...
kiowacountypress.net
14 小时
What are pharmacy benefit managers? A health economist explains
Pharmacy benefit managers started popping up in the late 1960s as providers of claims processing and administrative services ...
Opinion
18 小时
Opinion
Weight-loss drugs are great — but real food still matters | Opinion
Nearly 75% of Americans are classified as overweight or obese. Addressing our nation's health crisis requires much more than ...
Opinion
tdn
22 小时
Opinion
Lisa Jarvis column: The bar for successful obesity drugs is rising
Although Novo will still make a mind-blowing amount of money from its existing obesity drugs in the coming years (its ...
The Motley Fool
23 小时
2 Pharmaceutical Growth Stocks to Buy Now and Hold for Decades
Not at all. Novo Nordisk's investigational weight loss therapy, CagriSema, combines semaglutide (the active ingredient in ...
dailymemphian
1 天
‘It’s bonkers’ — how Ozempic, Wegovy change lives of those who struggle to lose weight
Unless the government intervenes to lower the price or forces insurers to cover the drugs, they will remain out of range for ...
24/7 Wall St
1 天
Novo Nordisk A/S (NVO) Price Prediction and Forecast 2025-2030
When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...
studyfinds
1 天
Young and restless: 37% of Gen Z skipping the gym, going straight to Ozempic
Plenty of people want to lose weight in 2025, but here's why many may actually get there thanks to GLP-1 drugs.
BioWorld
1 天
GLP-1 receptor agonists continue their global victory tour
GLP-1 receptor agonists (GLP-1RAs) on multiple fronts. They continued to expand into new indications, and provide their developers with both rich remuneration and scientific acclamation. There are now ...
Opinion
1 天
Opinion
A Diet Writer’s Regrets
No one has ever known so much about healthy eating and been less successful at following her own advice.
1 天
Sodium-ion, solar, and Wegovy maker: A look at NC’s 5 largest job announcements of 2024
Whether this year’s big job commitments sink or swim will be known in time. But for now, let’s explore the dreams.
2 天
The Zepbound Shortage Is Over — Here's What to Expect if You've Been Using an Off-Brand ...
Patients taking a compounded alternative to Eli Lilly's weight loss drug Zepbound will need to transition to the name-brand ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈